Shots:
- Earendil Labs has entered into a strategic collaboration with Sanofi to advance bispecific candidates for autoimmune & inflammatory diseases using Earendil’s discovery platform
- Under the deal, Earendil Labs will identify & optimize bispecific antibody candidates for autoimmune & inflammatory disease targets, while Sanofi will handle the development & worldwide commercialization of the products
- As per the deal, Earendil Labs will receive ~$160M in upfront & near-term milestone payments, along with development & commercial milestones, representing the total deal value of ~$2.56B, plus tiered royalties on net sales up to low double-digit percent
Ref: PRnewswire |  Image: Earendil Labs & Sanofi | Press Release
Related News: Sanofi Enters a ~$1.84B Global License Agreement with Earendil Labs for HXN-1002 & HXN-1003
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
